Filtered By:
Condition: Diabetes
Cancer: Cancer in Adolescents
Vaccination: Vaccines
Nutrition: Diets
This page shows you your search results in order of relevance.
Order by Relevance | Date
Total 2 results found since Jan 2013.
Hopkins Nursing—Dean on Chronic Disease / Pediatrics
body,#bodyTable,#bodyCell{
height:100% !important;
margin:0;
padding:0;
width:100% !important;
}
table{
border-collapse:collapse;
}
img,a img{
border:0;
outline:none;
text-decoration:none;
}
h1,h2,h3,h4,h5,h6{
margin:0;
padding:0;
}
p{
margin:1em 0;
padding:0;
}
a{
word-wrap:break-word;
}
.mcnPreviewText{
display:none !important;
}
.ReadMsgBody{
width:100%;
}
.ExternalClass{
width:100%;
}
.ExternalClass,.ExternalClass p,.ExternalClass span,.ExternalClass font,.ExternalClass td,.ExternalClass div{
line-height:100%;
}
table,td{...
Source: Johns Hopkins University and Health Systems Archive - July 27, 2017 Category: Nursing Source Type: news
New Analyses Suggest Favorable Results for STELARA ® (ustekinumab) When Used as a First-Line Therapy for Bio-Naïve Patients with Moderately to Severely Active Crohn’s Disease and Ulcerative Colitis
SPRING HOUSE, PENNSYLVANIA, October 25, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from two new analyses of STELARA® (ustekinumab) for the treatment of adults with moderately to severely active Crohn’s disease (CD) and ulcerative colitis (UC).1,2 In a modelled analysisa focused on treatment sequencing using data from randomized controlled trials, network meta-analysis and literature, results showed patient time spent in clinical remission or response was highest when STELARA was used as a first-line advanced therapy for bio-naïve patients with moderately to severely acti...
Source: Johnson and Johnson - October 25, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
